1
|
Chalasani N, Younossi Z, Lavine JE, et al:
The diagnosis and management of non-alcoholic fatty liver disease:
practice Guideline by the American Association for the Study of
Liver Diseases, American College of Gastroenterology, and the
American Gastroenterological Association. Hepatology. 55:2005–2023.
2012. View Article : Google Scholar
|
2
|
Abe N, Honda S and Jahng D: Evaluation of
waist circumference cut-off values as a marker for fatty liver
among Japanese workers. Saf Health Work. 3:287–293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Adams LA, Lymp JF, St Sauver J, et al: The
natural history of nonalcoholic fatty liver disease: a
population-based cohort study. Gastroenterology. 129:113–121. 2005.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Dunn W, Xu R, Wingard DL, et al: Suspected
nonalcoholic fatty liver disease and mortality risk in a
population-based cohort study. Am J Gastroenterol. 103:2263–2271.
2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ascha MS, Hanouneh IA, Lopez R, et al: The
incidence and risk factors of hepatocellular carcinoma in patients
with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. 2010.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Chatrath H, Vuppalanchi R and Chalasani N:
Dyslipidemia in patients with nonalcoholic fatty liver disease.
Semin Liver Dis. 32:22–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Musso G, Gambino R, Cassader M and Pagano
G: Meta-analysis: natural history of non-alcoholic fatty liver
disease (NAFLD) and diagnostic accuracy of non-invasive tests for
liver disease severity. Ann Med. 43:617–649. 2011. View Article : Google Scholar : PubMed/NCBI
|
8
|
von Volkmann HL, Havre RF, Løberg EM, et
al: Quantitative measurement of ultrasound attenuation and
hepato-renal index in non-alcoholic fatty liver disease. Med
Ultrason. 15:16–22. 2013.PubMed/NCBI
|
9
|
Festi D, Schiumerini R, Marzi L, et al:
Review article: the diagnosis of non-alcoholic fatty liver disease
- availability and accuracy of non-invasive methods. Aliment
Pharmacol Ther. 37:392–400. 2013. View Article : Google Scholar : PubMed/NCBI
|
10
|
Neuschwander-Tetri BA, Clark JM, Bass NM,
et al: NASH Clinical Research Network: Clinical, laboratory and
histological associations in adults with nonalcoholic fatty liver
disease. Hepatology. 52:913–924. 2010. View Article : Google Scholar
|
11
|
Alvarez F, Berg PA, Bianchi FB, et al:
International Autoimmune Hepatitis Group Report: review of criteria
for diagnosis of autoimmune hepatitis. J Hepatol. 31:929–938. 1999.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Lindor KD, Gershwin ME, Poupon R, et al:
American Association for Study of Liver Diseases: Primary biliary
cirrhosis. Hepatology. 50:291–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Matsumoto T, Yamasaki S, Arakawa A, et al:
Exposure to a high total dosage of glucocorticoids produces
non-alcoholic steatohepatits. Pathol Int. 57:388–389. 2007.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Khan N, Abbas AM, Whang N, et al:
Incidence of liver toxicity in inflammatory bowel disease patients
treated with methotrexate: a meta-analysis of clinical trials.
Inflamm Bowel Dis. 18:359–367. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sanyal AJ: American Gastroenterological
Association: AGA technical review on nonalcoholic fatty liver
disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI
|
16
|
Bedogni G, Miglioli L, Masutti F, et al:
Prevalence of and risk factors for nonalcoholic fatty liver
disease: the Dionysos nutrition and liver study. Hepatology.
42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
|
17
|
Anty R, Iannelli A, Patouraux S, et al: A
new composite model including metabolic syndrome, alanine
aminotransferase and cytokeratin-18 for the diagnosis of
non-alcoholic steatohepatitis in morbidly obese patients. Aliment
Pharmacol Ther. 32:1315–1322. 2010. View Article : Google Scholar
|
18
|
Iwamoto M, Yagi K, Yazumi K, et al: Eating
a healthy lunch improves serum alanine aminotransferase activity.
Lipids Health Dis. 12:1342013. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wu WC, Wu CY, Wang YJ, et al: Updated
thresholds for serum alanine aminotransferase level in a
large-scale population study composed of 34 346 subjects. Aliment
Pharmacol Ther. 36:560–568. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Verma S, Jensen D, Hart J and Mohanty SR:
Predictive value of ALT levels for non-alcoholic steatohepatitis
(NASH) and advanced fibrosis in non-alcoholic fatty liver disease
(NAFLD). Liver Int. 33:1398–1405. 2013. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xia MF, Yan HM, Lin HD, et al: Elevation
of liver enzymes within the normal limits and metabolic syndrome.
Clin Exp Pharmacol Physiol. 38:373–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Nomura K, Yano E, Shinozaki T and Tagawa
K: Efficacy and effectiveness of liver screening program to detect
fatty liver in the periodic health check-ups. J Occup Health.
46:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
23
|
Hu X, Huang Y, Bao Z, et al: Prevalence
and factors associated with nonalcoholic fatty liver disease in
Shanghai work-units. BMC Gastroenterol. 12:1232012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Simental-Mendía LE, Rodríguez-Hernández H,
Rodríguez-Morán M and Guerrero-Romero F: The alanine
aminotransferase to triglycerides ratio as a marker to identify
nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol.
24:1173–1177. 2012.PubMed/NCBI
|